We report long-term results of high-dose cyclophosphamide, etoposide and carboplatin with ABMT in 20 patients with metastatic breast cancer. Median age of the group was 41 years, ECOG performance status = 0 in 18 patients and 1 in two patients. Twelve patients had received adjuvant chemotherapy. Predominant sites of metastases were lung (eight), chest wall (four), liver (four), bone (three) and lymph nodes (three). Response to pretransplant chemotherapy was complete (CR) in four patients, partial (PR) in 10 patients and stable (SD) in five patients. After high-dose chemotherapy eight patients were in CR, six PR, four SD and one progressive disease. Two patients died of regimen-related toxicities (candidal sepsis and alveolar hemorrhage). With a median follow-up period of 55 months (minimum 48 months), 12 patients have died of recurrent breast cancer, one died of toxicity of salvage chemotherapy, two are alive with disease, two are alive and free of progressive disease. One patient with relapsed disease was lost to follow-up. Median event-free survival is 6 months and median overall survival is 17 months. All three of the long-term disease-free survivors had predominantly nodal disease. Two of these three patients presented with metastatic disease and received high-dose chemotherapy with ABMT as part of initial therapy for breast cancer; two of three attained CR to standard-dose cytoreductive therapy; none received doxorubicin-containing adjuvant chemotherapy. Keywords: high-dose chemotherapy; metastatic breast cancer; autologous bone marrow transplantation High-dose chemotherapy with autologous stem cell support is commonly used to treat metastatic adenocarcinoma of the breast. Such therapy is considered by many to be effective therapy for metastatic breast cancer despite the attendant risks, expense, and minimal evidence of long-term benefit.
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From 1990 to 1993 we treated 20 women with metastatic breast cancer with a unique high-dose combination of cyclophosphamide, etoposide and carboplatin supported by autologous bone marrow infusion. In general, ours was a poor risk group of patients, five of whom had no response to pretransplant cytoreductive therapy. With a minimum follow-up time of 4 years, we now present mature results of this high-dose regimen.
Materials and methods
Patients with metastatic breast cancer who had at least a stable disease response to most recent standard-dose (cytoreductive) chemotherapy were eligible for this study. All patients had either progressed on hormonal therapy or had estrogen receptor-negative tumors. All patients were required to have an ECOG performance status of 0-2 and have adequate end-organ function including serum creatinine р2.0 mg/dl, total bilirubin р2.0 mg/dl, FEV 1 , FVC and DLCO Ͼ 60% of predicted values, left ventricular ejection fraction Ͼ45% by MUGA or echocardiography and WBC Ͼ 4.0 × 10 9 /l and platelets Ͼ 100 × 10 9 /l. Patients with central nervous system metastases or metastases confined to bone only were excluded. Other pertinent patient characteristics are listed in Table 1 .
After initial cytoreductive therapy, patients received cyclophosphamide 60 mg/kg (n = 7) or 120 mg/kg (60 mg/kg daily for 2 days) (n = 13), etoposide 1200 mg/m 2 (240 mg/m 2 daily for 5 days) and carboplatin 1500 mg/m 2 (300 mg/m 2 daily for 5 days). Cryopreserved autologous bone marrow was thawed at the bedside and infused not less than 36 h after the final dose of chemotherapy. Patients were nursed in private rooms supplied with HEPA-filtered air. No prophylactic antibiotics or gut decontamination was employed. Hematopoietic growth factors were used in 13 of the 20 patients. Consolidative radiotherapy was given when appropriate after marrow recovery in responding patients. Response to high-dose therapy was defined as response status 60 days afer marrow reinfusion. Complete remission indicated disappearance of all measurable disease for a period of at least 4 weeks; partial remission was defined as a decrease by 50% in the sum of the products of the perpendicular diameters of all measurable lesions; stable disease, a Ͻ25% reduction or increase in the sum of the products of the two perpendicular products of all measurable lesions and the appearance of no new lesions for a period of at least 4 weeks.
Results
Our patients shared several features of high-risk disease including prior adjuvant chemotherapy, relative resistance to standard-dose chemotherapy (five patients with stable disease after cytoreductive therapy) and the presence of visceral disease. Details of patient characteristics and autotransplantation are found in Tables 1 and 2 . In general, toxicities of therapy were manageable (Table 3) . Two patients died of regimen-related toxicities: one on day +10 of disseminated candidiasis and one on day +39 of diffuse alveolar hemorrhage and the adult respiratory distress syndrome. One patient had a partial response to initial transplant and underwent a second autotransplant 7 months later after disease progression. She ultimately relapsed and died of recurrent breast cancer 26 months after the second course of high-dose therapy and autotransplant.
At evaluation 60 days after high-dose therapy, eight patients (40%) had achieved a CR, four of whom had converted from a partial response (PR) to CR. Six patients (30%) had responded partially and five had stable or progressive disease (Table 4) . With a median follow-up period of 55 months and a minimum follow-up period of 48 months, two patients (10%) remain alive and free of recurrent disease. One patient relapsed 60 months after ABMT and is currently receiving salvage chemotherapy. One patient is alive with active metastatic breast cancer 57 months after completing high-dose therapy. One patient who had persistent disease post-transplant was lost to follow-up 5 months after high-dose therapy. The median survival for the group as a whole is 17 months. All three longterm (Ͼ4 years) responders had metastatic disease confined to supraclavicular lymph nodes only. Two of these three women received ABMT as part of initial therapy for metastatic disease and all received consolidative radiotherapy to all known sites of disease (Table 5 ). Three additional patients also received post-transplant radiotherapy to sites of metastatic disease (bone, supraclavicular node, chest wall) but each of these patients developed progressive disease at 3, 10 and 16 months after transplantation, respectively. The median time to relapse or progressive disease for the 18 evaluable patients was 8 months. Event-free survival for the group is shown in Figure 1 . Among the 16 patients who experienced disease progression, 14 had disease progression at sites where disease had been present before transplantation. Two patients developed central nervous system metastases, but in neither patient was the CNS the sole site of progressive disease. Neither of the patients who developed CNS metastases had undergone imaging of the CNS prior to high-dose therapy.
Discussion
Long-term follow-up of our small group of patients finds disease-free and overall survivals that approximate those of similar larger trials of high-dose chemotherapy for metastatic breast cancer. [1] [2] [3] [4] Our patients represent a poor prognostic subgroup (heavily pretreated, less than partial reponse to standard-dose therapy) and several of them would have been excluded from entry into current highdose chemotherapy trials. In this report, two of 20 patients remain free of recurrence at a minimum of 4 years after high-dose chemotherapy. An additional patient had a disease-free interval of 5 years before relapse. These longterm disease-free survivors share the characteristics of low tumor burden, few sites of metastatic disease, chemosensitive disease and young age. As noted by others, these Table 4 Outcomes of high-dose chemotherapy with ABMT (n = 20)
Regimen-related death 2 Dead related to progressive disease 12 Dead related to drug toxicity during salvage therapy 1 Lost to follow-up 1 Alive with disease 2 Alive free of progression 2 777 Table 5 Characteristics of long-term disease-free survivors (DFS Ͼ 48 months) characteristics are nearly identical to those identified as predictors for long-term response to either standard-dose or high-dose chemotherapy. [5] [6] [7] [8] Post-transplant radiotherapy to all known sites of metastatic disease was feasible in six patients. Three of these were the long-term relapse-free survivors described above. The other three patients who received consolidative radiotherapy relapsed within 16 months of transplant. All four patients who relapsed did so at sites outside of the radiation ports. In general, patients who are candidates for consolidative radiotherapy are those with low volume, nonvisceral disease. The intrinsic value of post-transplant radiotherapy is unclear.
Overall, the toxicities of the high-dose chemotherapeutic regimen used in this study were acceptable. The 10% regimen-related mortality is in line with that reported in other studies in which autologous bone marrow was used to enhance hematopoietic recovery. This figure would likely have been lower if peripheral blood progenitor cells had been available for use. This combination of high-dose cyclophosphamide, etoposide and carboplatin appears to have an efficacy that is comparable to more frequently used regimens (eg cyclophosphamide, thiotepa, carboplatin or cyclophosphamide, cisplatin, carmustine) and may cause less pulmonary toxicity than some.
Recent reports indicate that between 50 and 70% of women with metastatic breast cancer can achieve complete remission if they are selected for treatment with high-dose chemotherapy. Among these patients, 10-25% will enjoy durable (Ͼ3 years) complete remissions. While these results appear better than those attainable with standarddose regimens, many have argued that patient selection bias could account for the apparent benefits of high-dose therapy. However, it should be noted that most trials of highdose chemotherapy have included only those breast cancer patients with poorest prognoses (eg visceral metastases, estrogen receptor-negative) which would influence the results in the direction of poorer outcomes. Attempts to improve results of a single cycle of high-dose chemotherapy by employing two or more cycles of high-dose therapy with stem cell support have not been successful to date. [9] [10] [11] Alternative strategies for the use of high-dose chemotherapy have also been studied. One trial performed at Duke University indicates that for patients who have achieved a complete response to standard-dose therapy, delaying high-dose chemotherapy with stem cell support until time of progression results in overall survival that is superior to that achieved by immediate high-dose therapy (median 3.2 vs 1.9 years). 12 To date, one prospective randomized trial comparing high-dose to standard-dose chemotherapy for the initial treatment of metastatic breast cancer has been published. 13 This study has been criticized frequently because of the use of a suboptimal standard-dose chemotherapy regimen and a suboptimal high-dose regimen. Nevertheless, women who received the high-dose arm achieved significantly more complete remissions (51 vs 4%) and a doubling of overall survival (median 90 vs 45 weeks). Similar randomized studies are currently under way in the United States.
In conclusion, our trial demonstrates that a relatively small fraction of women with metastatic breast cancer can enjoy long-term disease-free survival after high-dose chemotherapy with stem cell support. The clinical features of these long-term responders are well established and are shared by patients who have good outcomes to standarddose chemotherapy. Additional randomized studies are ongoing to further examine the role of high-dose chemotherapy in the treatment of metastatic breast cancer.
